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Abstracts A75
the ordered probit scale was conducted to evaluate the comparative efﬁ cacy of 
the biologics based on the Psoriasis Area and Severity Index (PASI) responder end-
points. The absolute probability of PASI 50, 75 and 90 responses were estimated. 
RESULTS: A total of 20 studies enrolling 10,108 psoriasis patients, including 1 head-
to-head trial of etanercept and ustekinumab, were identiﬁ ed and included in the NMA.
Thirteen studies evaluated TNF-alpha inhibitors (adalimumab  3, etanercept  6, 
inﬂ iximab  4), 5 studies evaluated T-cell modulators (efalizumab  5), and 3 studies 
evaluated ustekinumab. Baseline patient characteristics were comparable across the
trials. The estimated mean PASI 75 responses were as follows: inﬂ iximab (mean 80%;
95% CI 70–87%), ustekinumab 90 mg (74%; 68–80%), ustekinumab 45 mg (69%; 
62–75%), adalimumab (58%; 49–68%), etanercept 50 mg biw (52%; 45–59%), 
etanercept 25 mg biw (39%; 30–48%), efalizumab (26%; 21–32%), and supportive 
care/placebo (4%; 3–4%). CONCLUSIONS: Based on this analysis, all of the active 
treatments produced a greater response rate than placebo. Ustekinumab and inﬂ ix-
imab had the highest mean response rates followed in order by adalimumab, etaner-
cept and efalizumab. However, there was considerable overlap in the 95% conﬁ dence
intervals.
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OBJECTIVES: Acute otitis media (AOM) is a common childhood condition with viral
and bacterial causation. Routine immunization programs currently include 7-valent 
Pneumococcal Conjugate Vaccine (PCV-7), associated with AOM reduction caused by 
Streptococcus pneumoniae only. The study objective was to conduct a systematic lit-
erature review to identify current microbiological picture associated with AOM. 
METHODS: OVID (Medline, Current Content and International Pharmaceutical
Abstract databases), EMBASE, Google and Google Scholar engines were searched with
the following combination of key-words: “acute otitis media”, “bacteria$” and
“vir$”. Eligible articles were in English, published between 1995 and 2008, and 
described studies of pediatric AOM patients with cultures for bacterial and viral iso-
lates. RESULTS: Of the 398 articles screened, 24 separate studies were included (range
 25–623 subjects). Based on a ﬁ xed-effects meta-analysis across all studies, pathogens
isolated were more frequently bacterial (74%) than viral (19%). Compared with the 
15 international studies, U.S. studies recorded a similar isolation rate for bacterial
(73% vs. 74%) and higher isolation rate for viral pathogens (23% vs. 17%). Twenty-
three studies included data on the speciﬁ c bacterial pathogens cultured. Based on a 
ﬁ xed-effects meta-analysis of patients in these studies, S. pneumoniae and Haemophi-
lus inﬂ uenzae were isolated with similar frequency (35% vs. 36%) and Moraxella
catarrhalis at 6%. Slightly higher isolation rates of M. catarrhalis (10%) and lower 
rates of H. inﬂ uenzae (31%) were observed in U.S. patients, compared with interna-
tional patients. CONCLUSIONS: Bacterial pathogens are frequently associated with
AOM in pediatric populations worldwide and were isolated 3-times more often than 
viral pathogens. S. pneumoniae and H. inﬂ uenzae are the bacterial pathogens most
commonly isolated in AOM cases, with nearly equal frequency. A vaccine that 
addresses more than one cause of AOM would be expected to greatly reduce the 
clinical and economic burden associated with this common condition.
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OBJECTIVES: Risks and beneﬁ ts of TNF-alpha inhibitors are often presented using 
statistical descriptions that are difﬁ cult to directly translate for patients into a clini-
cally-meaningful context. The objective of this study was to illustrate the risks and 
beneﬁ ts of TNF-alpha inhibitors in relation to risks that patients understand. 
METHODS: We performed a number needed to treat analysis for psoriasis patients 
on TNFalpha inhibitors via a Medline and Embase search. We determined the number
needed to beneﬁ t and the number needed to harm with TNF-alpha inhibitor treatment. 
We compared the risk of serious adverse events (SAE) from treatment with a TNF-
alpha inhibitor to the risk of death from driving a car. The risk analyses were limited
to tuberculosis, lymphoma, and demyelinating disease. RESULTS: The numbers
needed to beneﬁ t were 2.1 for etanercept, 1.4 for inﬂ iximab, and 1.6 for adalimumab.
Depending on adverse event, the numbers needed to harm ranged from 380 to 360,000 
treated patients per year. Screening prior to the initiation of TNF-alpha inhibitor 
therapy reduces risk of tuberculosis. Patients are about as likely to die in a car accident
as have a serious adverse event from TNF-alpha inhibitor treatment. CONCLU-
SIONS: All 3 of the TNF-alpha antagonists have remarkable efﬁ cacy in patients with 
severe psoriasis. The risks of serious adverse events are relatively rare and comparable 
to risks patients take on a regular basis such as driving a car. For severe psoriasis, the 
beneﬁ ts of TNF-alpha inhibitors may greatly outweigh the risks for many patients.
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OBJECTIVES: To assess the cost differences between adalimumab and etanercept for
chronic plaque psoriasis. METHODS: A model was constructed to compare the drug
acquisition costs for adalimumab and etanercept for chronic plaque psoriasis for a
hypothetical primary care trust. The number of patients eligible for anti-TNF treat-
ment was taken from published sources. Patients were assumed to receive either etan-
ercept intermittently, mixed intermittent and continuous, continuous, or continuous 
adalimumab. Market research demonstrated that about 36% of patients are likely to 
receive continuous etanercept. Adalimumab, in contrast can not be used intermittently. 
Costs were estimated from a UK payer perspective. The time horizon is three years.
RESULTS: We estimated that the hypothetical PCT would cover 250,000 people, 
which is approximately the average size of a PCT in the UK. Of these 195,000 would 
be q 18 years of age. thirty-ﬁ ve patients would meet the criteria for either adalimumab
or etanercept. Providing that all patients would receive intermittent etanercept this 
would cost the NHS GBP 722,190, if 36% receive continuous etanercept and the rest 
intermittent etanercept it would cost GBP 816,453, whilst if all patients would receive 
continuous etanercept it would cost GBP 975,975. All patients receiving continuous 
adalimumab would cost GBP 1,001,000. CONCLUSIONS: Our model found poten-
tial for cost savings for PCTs from using etanercept instead of adalimumab, within 
the recommended patient groups for chronic plaque psoriasis. Savings will be increas-
ingly important if the proportion of eligible patients who receive treatment increases 
from the current level.
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OBJECTIVES: To compare the use of prostaglandin analogues namely, Bimatoprost,
Travoprost and Latanoprost, in the treatment of glaucoma by conducting a cost 
effectiveness analysis considering medication related adverse event and patient-
persistence as indirect costs. METHODS: The study was conducted from a third-
party payer’s (Medicare) perspective with a time-frame of 12 months. Literature 
review was conducted to estimate medical-visit costs, average reduction in intra-ocular
pressure (IOP) in mm Hg, medications related adverse event and patient-persistence
to the pharmacotherapy. Average wholesale price (AWP) for the drug considered
(obtained from the REDBOOK-2007), mean number of drops per bottle (according 
to the best instillation method), days per bottle, and annual usage of bottles for these 
drugs were also obtained from published literature to determine the annual cost
associated with prostaglandin pharmacotherapy. DATA (version 3.0) software package 
was used to perform the decision analysis. Incremental cost-effectiveness ratios (ICER)
were calculated using intra-ocular-pressure reduction as efﬁ cacy estimate. Sensitivity 
analyses were conducted by changing the cost information by 25% to account for the 
variation in drug administration. A discounting rate of 5% was used to project all 
cost estimates to year 2008. RESULTS: The decision-analysis indicated Travoprost 
to be slightly inexpensive among the three prostaglandins (expected value $616.33),
followed by Bimatoprost (expected value $618.73) and Latanoprost (expected 
value $626.29). Compared with Latanoprost, Travoprost and Bimatoprost provided
a higher IOP-reduction with ICER of $(9.96) and $(7.56) respectively. Results
of sensitivity analyses were robust to the decision analysis performed. CONCLU-
SIONS: Based on our analysis Travoprost and Bimatoprost was more cost-effective 
than Latanoprost. Health care decision-makers should consider the effect of adverse 
drug events and persistency proﬁ les on the direct medical costs to prioritize the pros-
taglandin analogues for long-term treatment of glaucoma. Further, analyses using 
adherence data for speciﬁ c patient groups can provide valuable information to decision
makers.
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OBJECTIVES: To calculate the cost per clinical success (CS) in the antibiotic treatment 
for complicated skin and skin-structure infections (CSSI) in Mexican Social Security
Institutions in Mexico. METHODS: The use of either i.v. Daptomycin (DAP), i.v. 
Vancomycin (VAN) or i.v. Linezolid (LIN) as ﬁ rst-line and second-line antibiotic
therapy was compared in a cost-effectiveness study. Data was collected from a sys-
tematic review which included the most recent published articles measuring clinical
improvement, length of stay at hospital services and adverse events due to the use of 
